secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005425
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT reports 65% ORR for BBO-8520, first panKRAS response in PDAC, no hyperglycemia with BBO-10203
--------------------------------------------------------------------------------

- BBO-8520 monotherapy: 65% ORR (11/17), 66% 6-month PFS, including one complete response; all 5 STK11/KEAP1 co-mutant patients achieved PR.
- BBO-8520 + pembrolizumab: all 8 evaluable patients had tumor reduction; 3/3 front-line and 2/5 prior KRAS G12C inhibitor patients achieved PR.
- BBO-11818 panKRAS inhibitor: first monotherapy PR in pancreatic ductal adenocarcinoma (44% tumor reduction); dose-proportional exposure covering G12D/G12V at 600 mg BID.
- BBO-10203 RAS:PI3Kα breaker: no hyperglycemia of any grade, no baseline HbA1c/glucose restrictions; 500 mg QD selected for expansion; combination studies initiated.
- Combination studies of BBO-8520, BBO-11818, and BBO-10203 with each other and with standard-of-care expected to open in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526005425/0001193125-26-005425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526005425/d941846d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer